Related Experiment Video
Updated: Sep 23, 2026
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Efficacy of goserelin combined with laparoscopic surgery for endometriosis and its effects on ovarian function and
Wanying Ma1, Tao Li1, Yang Ou1
1Department of Obstetrics and Gynecology, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu Chengdu 610031, Sichuan, China.
Objective:
To investigate the efficacy of goserelin (GOS) combined with laparoscopic surgery (LS) in the treatment of endometriosis (EMS), and its effects on ovarian function and oxidative stress (OS).
Methods:
A total of 208 patients with EMS were enrolled in this retrospective study. The control group (n=102) received LS alone, while the research group (n=106) received GOS combined with LS. The endpoints included therapeutic efficacy, time to ovulation resumption, time to menstrual recovery, dysmenorrhea, pelvic pain, ovarian function indices [follicle-stimulating hormone (FSH), estradiol (E2), luteinizing hormone (LH)], inflammatory markers [interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α], OS indices [reactive oxygen species (ROS), malondialdehyde (MDA), advanced oxidation protein products (AOPP)], adverse reactions, and postoperative recurrence. Subgroup analyses were performed by stratifying patients based on age, ovarian cyst diameter, and American Society for Reproductive Medicine (ASRM) classification.
Results:
Compared to the control group, the research group showed the following significant differences: (1) The total effective rate was notably higher, and the time to ovulation resumption and menstrual recovery was significantly shorter; (2) Postoperative dysmenorrhea and pelvic pain were evidently relieved, and the postoperative levels of FSH, E2, LH, IL-1β, IL-6, TNF-α, ROS, MDA, and AOPP were statistically lower; (3) The recurrence rates at 6 months and 1 year after surgery were significantly reduced (all P<0.05). There was no significant difference in the overall incidence of adverse reactions between groups (P>0.05). The interactions of age, ovarian cyst diameter, and ASRM classification with therapeutic efficacy were not statistically significant (all P>0.05).
Conclusion:
On the basis of LS, the addition of GOS is effective for the treatment of EMS, and it exerts positive effects on improving ovarian function and inhibiting OS.
